Brazilian Strategy to Create a Local Biotech and CMO Industry

Flavio Valente of EMD Serono joined us for World Biosimilar Congress USA 2016 to discuss ‘ Brazilian strategy to create a local biotech and CMO industry ‘. Download this presentation to understand more about: EMD Serono and its Biosimilars unit Biosimilars opportunity in Brazil Productive Development Partnership (PDPs) Merck – Binovis Partnership Brazilian Biotechnology and CMO Industry and more ! …

What happens to Biosimilars being developed under 505b (2)?

Nitesh Dave of Biocon joined us for World Biosimilar Congress USA 2016 to discuss what happens to biosimilars being developed under 505b (2). Download this presentation to understand more about: Key features of 505b (2) Key features of 351k (1, 2) Products approved under 505b (2) Path ahead for products under development and more! Get your copy here! If you’re interested …

Vladimir Hanes of Amgen's 2015 Presentation

Amgen’s meaningful biosimilar development programs

We were excited to have Vladimir Hanes, Medical Director of Oncology/Biosimilars at Amgen, share his expertise on the structure, function, and the science of biosimilarity in designing meaningful biosimilar development programs at last year’s World Biosimilar Congress USA. Download his presentation now > You can now download Vladimir’s presentation to find out more about: FDA & EU definitions of biosimilars …

Bloomberg Biosimilar Survey

Take part in the Biosimilars Survey – Bloomberg Intelligence

Bloomberg Intelligence have launched the Biosimilars Survey. This is your opportunity to have your voice heard. Take part in the survey here > All responders will receive a white paper and analysis of the results. That’s not all! All responders will also receive a 15% discount code off the delegate ticket price for World Biosimilar Congress USA 2015, where Bloomberg will be …

Designing, Clinical, Program, Biosimilar, Personal, Perspective,

Designing a Clinical Program for a Biosimilar: A personal perspective

At the Biosimilar Drug Development World Europe event 2014, Uwe Gudat, Merck Serono, gave a presentation on “Designing a Clinical Program for a Biosimilar: A personal perspective ” Download and learn: Innovator Clinical Development: A primer Biosimilar Clinical Development: Basics Biosimilar Clinical Development: Details Biosimilar Clinical Development: Conclusions Download Presentation Found this interesting? Join us at next year’s Biosimilar Drug Development World …

biosimilar, biosimilar drug development, biosimilar perspectives, industry, intelligence

Download ebook: Biosimilar Industry Intelligence – 5 Key Perspectives

Change in the biosimilars industry is really picking up pace. The regulatory environment is becoming ever more stable and organisations are continuing to explore development, clinical and commercial strategies that offer genuine value to them, healthcare providers and most importantly, the patient. It is a busy time for the industry, but it is important to know the latest regulatory and industry developments, realise the …

clinical, pharmacology, biosimilar, biosimilars, biosimilar drug development congress

Biosimilars: A Clinical Pharmacologist’s view

At the Biosimilar Drug Development World Europe event 2014, Malcom Mitchel, Senior Medical Fellow, Eli Lilly, gave a talk on “Biosimilars: A clinical Pharmacologist’s view”. Download and learn: Method of administration Subject disposition Secondary PK analysis Conclusions on clinical pharmacology Best study Download Presentation Found this interesting? Join us at next year’s Biosimilar Drug Development World Europe event happening this 4-5 …

Cadila’s biosimilar at 20% of Humira price

You heard it right, the new biosimilar of adalimumab (brand name: Humira by Abbvie) was launched by Zydus Cadila with the name of Exemptia in India. This is the first biosimilar of adalimumab which is currently priced at one-fifth of Humira’s. (Read full article here) Biosimilars are significant biopharmaceutical products in  many countries in Asia. These biological products are similar, or  highly …

Financial, Forecast, Opportunity, Biosimilar, Medicine, Global, Healthcare, Marketplace

Financial Forecast: Opportunities For Biosimilar Medicines In The Global Healthcare Marketplace

At the Biosimilar Drug Development World Europe event 2014, Ashwin Pai, Jefferies International, gave a presentation on “Financial Forecast: Opportunities For Biosimilar Medicines In The Global Healthcare Marketplace.” Download and learn: Biosimilars – Where Do We Stand Today? What Does The Future Hold? Emerging Markets – Opportunity Large Than Previously Expected Developed Markets – Wide Differences Across Markets And Molecules What …